TY - JOUR T1 - Performance of three SARS-CoV-2 immunoassays, three rapid lateral flow tests and a novel bead-based affinity surrogate test for the detection of SARS-CoV-2 antibodies in human serum JF - medRxiv DO - 10.1101/2021.02.07.21251062 SP - 2021.02.07.21251062 AU - Manuel Krone AU - Julia Gütling AU - Johannes Wagener AU - Thiên-Trí Lâm AU - Christoph Schoen AU - Ulrich Vogel AU - August Stich AU - Florian Wedekink AU - Jörg Wischhusen AU - Thomas Kerkau AU - Niklas Beyersdorf AU - Silvana Klingler AU - Simone Backes AU - Lars Dölken AU - Georg Gasteiger AU - Oliver Kurzai AU - Alexandra Schubert-Unkmeir Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/08/2021.02.07.21251062.abstract N2 - For the control of immunity in COVID-19 survivors and vaccinated subjects there is an urgent need for reliable and rapid serological assays.Based on samples from 63 COVID-19 survivors up to seven months after symptom onset, and on 50 serum samples taken before the beginning of the pandemic, we compared the performance of three commercial immunoassays for the detection of SARS-CoV-2 IgA and IgG antibodies (Euroimmun SARS-COV-2 IgA/IgG, Mikrogen recomWell SARS-CoV-2 IgA/IgG, and SERION ELISA agile SARS-CoV-2 IgA/IgG) and three rapid lateral flow (immunochromatographic) tests (Abbott Panbio COVID-19 IgG/IgM, NADAL COVID-19 IgG/IgM, and Cleartest Corona 2019-nCOV IgG/IgM) with a plaque-reduction neutralization test (PRNT50) representing the gold standard. In addition, we report and validate a novel, non-commercial flow cytometry bead-based surrogate test.57 out of 63 PCR-confirmed COVID-19 patients (90 %) showed neutralizing antibodies. The sensitivity of the seven assays ranged from 7.0 % to 98.3 %, the specificity from 86.0 % to 100.00 %. Only one commercial immunoassay showed a sensitivity and specificity of greater than 98 %. These data indicate abundant interassay variability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Federal Ministry for Education and Science (BMBF) within the program InfectControl (project COVMon, grant-No 03COV26A) and the Free State of Bavaria with COVID-research funds provided to the University of Wuerzburg, Germany.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee University Hospital WuerzburgAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data shown in the manuscript is available upon request from the corresponding author. ER -